Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639626 · ClinicalTrials.gov registry record · Phase 2
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
A Phase 2 study, sponsored by Nationwide Children's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00639626 is a Phase 2 study that was terminated before completion, run by Nationwide Children's Hospital. The registered enrollment target is 6 participants.
The verdict
NCT00639626, a Phase 2 study, was terminated before completion, sponsored by Nationwide Children's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a study to find out if Levemir® (a long acting or basal insulin) is safe and effective in treating cystic fibrosis related diabetes (CFRD).
Interventions
- DRUG insulin detemir [rDNA origin] injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639626
The ClinicalTrials.gov registry entry for NCT00639626 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin detemir [rDNA origin] injection is the first listed.
NCT00639626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639626 about?
NCT00639626 is a clinical study titled "Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)". This is a study to find out if Levemir® (a long acting or basal insulin) is safe and effective in treating cystic fibrosis related diabetes (CFRD).
What is the current status of trial NCT00639626?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00639626?
The interventions under investigation include: insulin detemir [rDNA origin] injection (DRUG).
Who is sponsoring clinical trial NCT00639626?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.